AzTrials
AzTrials

Neuromuscular BlockadeNCT06220136

Comparison of the Performances of the cTOFR and the mTOFR During Reversal of Deep Neuromuscular Blockade With Sugammadex

An observational study of Neuromuscular Blockade and Anesthesia, General, run by Ankara University at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

It is known that deep neuromuscular block improves surgical conditions, especially during laparoscopic abdominal surgery. Based on this, in the Perioperative Neuromuscular Blockade Management guide published by the ESAIC association in 2022, it is recommended to deepen the level of neuromuscular blockade in cases… Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Neuromuscular Blockade, Anesthesia, General
What is being tested?
TOFscan monitoring
Type of treatment
Medical device
How many people
200 participants
Where
1 siteTurkey (Türkiye)
Study dates
1 Jun 2024to 1 Jul 2026
How long will I take part?
2 Days
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Surgeries where neuromuscular blockers are used under general anesthesia

Who may be able to join

  • Age: 18 - 65 (not including 65)
  • BMI: 18.5-24.9

Who cannot join

  • Liver and kidney disease
  • Non-consenting
  • Emergency surgeries
  • Muscle disease
  • Allergy to rocuronium and sugammadex
  • Patients predicted to have difficult mask ventilation or difficult intubation
  • Pregnant and breastfeeding women

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Ankara University

    Ankara, Altındağ, 06230

Other trials in Turkey (Türkiye)

About this study

Official title: Comparison of the Performances of the Train-of-Four Ratio and the Modified Train-of-Four Ratio During Reversal of Deep Neuromuscular Blockade With Sugammadex

It is known that deep neuromuscular block improves surgical conditions, especially during laparoscopic abdominal surgery. Based on this, in the Perioperative Neuromuscular Blockade Management guide published by the ESAIC association in 2022, it is recommended to deepen the level of neuromuscular blockade in cases where surgical conditions need to be improved. Sugammadex should be used to quickly and reliably reverse deep neuromuscular blockade. TOFScan, a 3-dimensional acceleromyograph for neuromuscular monitoring, has become widely used in recent years. With this monitor, it has been shown that in addition to the classical train-of-four ratio (cTOFR), the modified train-of-four ratio (mTOFR) can be used during the spontaneous recovery of nondepolarizing neuromuscular blockade. In a study conducted by Schmartz et al. in 2021, it was shown that mTOFR, which is the ratio of T4 to the reference stimulus, was compiled later than cTOFR. Therefore, it is suggested that the mTOFR value is a better determinant for safe extubation.

Read the detailed description

Neuromuscular blockers (NMB) agents are commonly used drugs in anesthesia for facilitating airway management, improving surgical conditions, and inducing immobility in critical situations. As a natural consequence of their use, postoperative residual neuromuscular block has been associated with serious postoperative complications such as upper airway obstruction, reintubation, atelectasis, pneumonia, prolonged stay in the post-anesthesia care unit (PACU), and decreased patient satisfaction. The incidence of residual block at the end of surgery and/or in the PACU is approximately 64% according to the literature .

Various factors contribute to the high incidence of residual neuromuscular block, including variability in the duration of action of neuromuscular blocker agents, variability in the time it takes for antagonist drugs to restore neuromuscular function, and clinicians' reliance on unreliable methods for assessing neuromuscular strength, such as continuous head lifting, grip strength, or respiratory measurements (e.g., tidal volume, inspiratory force), and the subjective evaluation of peripheral nerve stimulation responses . Residual neuromuscular block is a significant patient safety concern, and its detection and risk reduction are crucial for improving patient outcomes. One of the objective methods for assessing neuromuscular function is the Train of Four (TOF), which is an acceleromyographic peripheral nerve stimulator.

The effectiveness of TOF as an objective and quantitative assessment of neuromuscular block and its role in reducing postoperative complications has been demonstrated in numerous studies. In 2023, the "American Society of Anesthesiologists Practice Guidelines for Monitoring and Antagonism of Neuromuscular Blockade" presented it with a moderate level of evidence and a high recommendation level. Likewise, in 2023, the European Society of Anesthesiology and Intensive Care's "Perioperative Management of Neuromuscular Blockade" guideline recommended TOF monitoring as part of routine perioperative monitoring with a 1B level of evidence .

TOF involves delivering four brief electrical impulses to a peripheral nerve at a frequency of 2 Hz and evaluating the resulting "twitches." The ratio of the response to the fourth stimulus to the response to the first stimulus (T4/T1) is referred to as the TOF ratio. Acceptable recovery of neuromuscular function is defined as a TOF ratio greater than or equal to 0.9. In a prospective study conducted in 2022 by Schmartz and colleagues, they compared a modified TOF ratio (T4/Tr) to the classic TOF ratio (T4/T1) against a reference measurement and demonstrated that the T4/Tr ratio is a better indicator of readiness for adequate recovery and safe extubation from non-depolarizing neuromuscular blockade compared to the classic TOF ratio (T4/T1) . This result suggests that the classic TOF ratio may overestimate the degree of true neuromuscular recovery, potentially leading to early tracheal extubation, increased risk of postoperative pulmonary complications, and endangering patient safety.

The aim of our study is to determine whether the differences in mTOF/classic TOF durations, as shown by Schmartz and colleagues in spontaneous neuromuscular recovery, also result in significant differences when rocuronium is reversed with sugammadex.

PROTOCOL:

Consent will be obtained from patients who meet the inclusion criteria during preoperative evaluation. After being admitted to the operating room, demographic information will be recorded and the following steps will be routinely performed.

Monitoring: ECG + NIKB + SpO2 + BIS + acceleromyography + body temperature Premedication: 1 mic/kg fentanyl and 0.05 mg/kg midazolam Preoxygenation: 3 minutes using 80% oxygen + 20% air with mask Anaesthesia Induction: 1 mic/kg fentanyl + 1 mg/kg lidocaine + 1 mg/kg propofol (BIS-guided) + 0.5 mic/kg breviblock Neuromuscular monitoring: After all standard preparations Set current to 50 mA Cancel T4/T2 TOF warning (1-2 times) 50 Hz tetanic stimulation for 5 s Calibration TOF warning until stabilisation is achieved (TOFr changes by less than 5% for 2-5 minutes) Muscle relaxation 1 mg/kg (according to ABW, actual) rocuronium/5 s bolus Analgesia 1 mic/kg fentanyl Intubation: Intubation with appropriately sized ETT when BIS is between 40-60, cTOFR: 0% Maintenance: BIS-guided TIVA anaesthesia (total 1 l/min oxygen and air mixture with FiO2 with SpO2 between 95-98) Muscle relaxant maintenance: PTC is measured at 5 minute intervals. PTC 1-2 is targeted. 5 mic/kg/min infusion is started. PTC measurement is continued. When PTC is 0, muscle relaxant infusion is stopped.

Intraoperative follow-up: PTC is measured at 5 minute intervals

  • Stop rocuronium infusion if PTC is 0
  • PTC 1-2 targeted values, 5 mic/kg/min maintenance rocuronium infusion is started.
  • If PTC increases to 3 and above, 0.1 mg/kg bolus dose is added to the infusion. At the end of surgery : Anaesthetic drugs are switched off. PTC : 1-2, cTOFr measurement is started at 15 s intervals. 4 mg/kg sugammadex is administered. If cTOFR does not increase to 90% and above within 5 minutes, an additional dose of neostigmine is administered (0.02 mg/kg dose, without atropine).

Extubation: Extubation is performed when BIS is above 90% and cTOFR is 90% and above.

The patient is followed in the operating room until cTOFR and mTOFR are 100%.

During the perioperative course, the patient's TOFscan (cTOFR - mTOFR) data, the amount of neuromuscular blockers used, and the need for reversal medication are recorded.

STATISTICAL METHODOLOGY:

Sample Size The sample size required for the study was based on the difference between classical TOF and mTOF in neuromuscular recovery with Sugammadex. Accordingly, the required sample size for this study was calculated as 199 when the sample calculation was performed with the paired t test in dependent groups at 80% power and 0.05 significance level for a value of 0.2 indicating a low magnitude effect.

GPOWER 3.1 was used for sample calculation. Source: Cohen, J (1988). Statistical Power Analysis for the Social Sciences (2nd. Edition). Hillsdale, New Jersey, Lawrence Erlbaum Associates.

Statistical Methods Descriptive statistics will be given as frequency (%) for categorical variables, mean ± standard deviation and median (minimum-maximum) for continuous variables. In the comparison of dependent groups, paired t test will be used when the assumption of normal distribution is met and Wilcoxon test will be used when the assumption of normal distribution is not met. Statistical significance level will be accepted as p<0.05. The evaluation of the data will be done in SPSS 11.5 for Windows programme.

Being tested
TOFscan monitoring
Keywords
neuromuscular blockade, neuromuscular junction monitoring, TOFscan, modified TOF ratio

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TOFscan monitoringDevice

    observation and data recording

Study groups in NCT06220136
Study groupRoleWhat they receive
single grouprocuronium drug administration TOFscan monitoring administration of sugammadex drug recording of classical TOF and modified TOF values
Receives: Device: TOFscan monitoring

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. time

    Comparison of classical and modified TOF rates to reach 90% and above

    Measured: 15 minutes

Secondary outcomes (1)
  1. time

    Comparison of the time to reach 100% for classical and modified TOF rates

    Measured: 30 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Jan 2024
  2. Study start1 Jun 2024
  3. Primary completion1 Jul 2026
  4. Study completion1 Jul 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
200 participants (actual)
Target duration
2 Days
IDs, dates and publications
ClinicalTrials.gov ID
NCT06220136
Sponsor's protocol ID
1357Hg*
Status last verified
Jul 2026
First submitted
2 Jan 2024
Last updated
28 Jul 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block. Anesth Analg. 2010 Jul;111(1):120-8. doi: 10.1213/ANE.0b013e3181da832d. Epub 2010 May 4.

    PubMed 20442260
  • Thilen SR, Weigel WA, Todd MM, Dutton RP, Lien CA, Grant SA, Szokol JW, Eriksson LI, Yaster M, Grant MD, Agarkar M, Marbella AM, Blanck JF, Domino KB. 2023 American Society of Anesthesiologists Practice Guidelines for Monitoring and Antagonism of Neuromuscular Blockade: A Report by the American Society of Anesthesiologists Task Force on Neuromuscular Blockade. Anesthesiology. 2023 Jan 1;138(1):13-41. doi: 10.1097/ALN.0000000000004379.

    PubMed 36520073
  • Fuchs-Buder T, Romero CS, Lewald H, Lamperti M, Afshari A, Hristovska AM, Schmartz D, Hinkelbein J, Longrois D, Popp M, de Boer HD, Sorbello M, Jankovic R, Kranke P. Peri-operative management of neuromuscular blockade: A guideline from the European Society of Anaesthesiology and Intensive Care. Eur J Anaesthesiol. 2023 Feb 1;40(2):82-94. doi: 10.1097/EJA.0000000000001769. Epub 2022 Nov 15.

    PubMed 36377554
  • Schmartz D, Bernard P, Sghaier R, Fils JF, Fuchs-Buder T. A modified TOF-ratio to assess rocuronium-induced neuromuscular block: a comparison with the usual TOF-ratio. Anaesth Crit Care Pain Med. 2022 Aug;41(4):101088. doi: 10.1016/j.accpm.2022.101088. Epub 2022 Apr 27.

    PubMed 35489709

Questions about this trial

What is this clinical trial studying?

An observational study of Neuromuscular Blockade and Anesthesia, General, run by Ankara University at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

time (time frame: 15 minutes). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06220136, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jul 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in